Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats.

Daniel J NesbittDaniel P JinJoseph W HoganJenny YangHaidee ChenPhilip A ChanMelissa J SimonMatthew VargasEwa KingRichard C HuardUtpala BandyChristopher D HillyerLarry L Luchsinger

Published in: BMC infectious diseases (2021)

These data imply that seroconversion, and thus infection, is likely not widespread within this population. We conclude that IgG LFAs and HTSAs are suitable to conduct seroprevalence assays in random populations. More studies will be needed using validated serological tests to improve the precision and report the kinetic progression of seroprevalence estimates.

Keyphrases

sars cov
high throughput
electronic health record
respiratory syndrome coronavirus
big data
machine learning
single cell
artificial intelligence
genetic diversity